AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00973245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 20mg od
Study NCT00973245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin based on target INR values
Study NCT01743040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CADence
Description: Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report.
Study NCT02211066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02211066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT03409250 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab, Lucentis
Description: Intravitreal injection with Lucentis (Ranibizumab)
Study NCT00828750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag oral tablets
Description: Eltrombopag oral tablets once daily
Study NCT02337881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipen
Description: The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
Study NCT02337881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
Study NCT02816229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of endobronchial valve
Description: One or more endobronchial one- way valves will be inserted into the appropriate lung regions
Study NCT01710098 — intervention group
Intervention type: DRUG
Intervention: Degarelix
Description: subcutaneous injection
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DMPA
Description: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral contraceptives
Description: Oral contraceptives (any variety of formulations are permitted)
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptives
Description: Oral contraceptives (any variety of formulations are permitted)
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implanon®
Description: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ParaGard®
Description: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Study NCT01299116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena®
Description: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
Study NCT03671915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: collection of glucose data
Study NCT03671915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: collection of glucose data
Study NCT03671915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Insulin Pump
Description: Insulin delivery
Study NCT03671915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Insulin Pump
Description: Insulin delivery
Study NCT03671915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabeloop Software (Model predictive control)
Description: Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study NCT03671915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring (Telemedicine)
Description: Remote follow up by care health providers team
Study NCT01123707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole oral capsules
Study NCT01123707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram oral capsules
Study NCT01776723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
Study NCT03720002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HF2
Description: placebo
Study NCT03720002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HF2
Description: placebo
Study NCT04016844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation or SHAM
Description: A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used.
Study NCT02172404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo capsule administered via the HandiHaler®
Study NCT03997656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: standard health education from primary care providers in the clinic
Study NCT02172404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipratropium metered dose inhaler (MDI)
Study NCT03465267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo power
Description: Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day.
Study NCT03465267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo spring
Description: Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day.
Study NCT03216746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral orientation and App for smartphone
Description: 66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
Study NCT03216746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral orientation
Description: 71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
Study NCT03216746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video orientation and App for smartphone
Description: 63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
Study NCT03216746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video orientation
Description: 63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Sulfated Dextran
Description: Inhibitor of instant blood-mediated inflammatory reaction
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulant
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Cell proliferation inhibitor, Transplantation (immunosuppressive)
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Cell proliferation inhibitor, Transplantation (immunosuppressive)
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Cell proliferation inhibitor, immunologic (immunosuppressive)
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Cell proliferation inhibitor, immunologic (immunosuppressive)
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Calcineurin inhibitor
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Calcineurin inhibitor
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Calcineurin inhibitor, immunosuppressant
Study NCT03577028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 Fixed IV 1.3 to 150 ng/kg
Description: Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
Study NCT03577028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 Prime Step IV 36 ng/kg Target
Description: Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
Study NCT03577028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 1 Prime Step IV 225-300 ng/kg Target
Description: Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
Study NCT03577028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 2 Prime Step IV 300 ng/kg Target
Description: Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Calcineurin inhibitor, immunosuppressant
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: Monoclonal IL-2 receptor blocker
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Monoclonal IL-2 receptor blocker
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Monoclonal IL-2 receptor blocker
Study NCT00790439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Monoclonal IL-2 receptor blocker
Study NCT00790439 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Pancreatic Islet Cells
Study NCT00790439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Study NCT02367703 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic hysterectomy
Study NCT02367703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic hysterectomy
Study NCT01257958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19 nor vitamin d
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole tablet
Description: Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole tablet
Description: Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clarithromycin
Description: The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
Study NCT03362281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin and clarithromycin
Description: The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
Study NCT01523548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide
Description: 150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
Study NCT02319031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Study NCT02319031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Study NCT02319031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT02139137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training - active
Description: Cognitive training using working memory span task
Study NCT02139137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training - sham
Description: Sham training condition
Study NCT01406587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP4001
Description: 50 mg, 1 dose every 12 hours x 4 doses
Study NCT01406587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP4001
Description: 100 mg, 1 dose every 12 hours x 4 doses
Study NCT01406587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP4001
Description: 200 mg, 1 dose every 12 hours x 4 doses
Study NCT01406587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 dose every 12 hours x 4 doses
Study NCT03815214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial meal replacement program
Description: Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
Study NCT03815214 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Counseling
Description: Participants will receive one 45-minute counseling session on a healthy diet
Study NCT02390882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02390882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0412 capsule
Description: Tamsulon high dose
Study NCT02390882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402 capsule
Description: Tamsulon high dose
Study NCT01224197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100 or 200 mg capsule, one single dose
Study NCT01224197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100 or 200 mg capsule, once daily for 5 days
Study NCT01823497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be used to control pain post-surgery.
Study NCT00238355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: 70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
Study NCT00238355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: 6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
Study NCT03071276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given orally on days 1,3,8,10,22 and 24 of each cycle
Study NCT03071276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Study NCT03071276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Study NCT03071276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate/hydrocortisone/cytarabine
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Study NCT03833778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intervention group
Description: The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
Study NCT01513278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APN201
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).